Tech Meridian ← ENTITY INDEX
PROMY MERIDIAN RU

COMPANY · ENTITY #9931

Eli Lilly

Related event timeline, sources and context from the news index.

EVENT TIMELINE

2

STARTUPS · 2 SOURCES · TechCrunch AI · The Decoder

Isomorphic Labs raises $5B Series C to push AI-designed drug candidates toward clinical trials

Isomorphic Labs, the AI drug-discovery spinout from DeepMind, raised $5 billion in a Series C round co-led by Greenoaks and Sequoia Capital with participation from Andreessen Horowitz and existing backers including GV, CapitalG, Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund. The company says it will use the funding to further develop its AI drug-design engine — built on techniques from DeepMind’s AlphaFold work — and to advance AI-designed candidates that have shown reported positive preclinical results in oncology and immunology toward clinical trials; it has partnerships with Eli Lilly, Novartis and Johnson & Johnson and did not disclose a valuation (Bloomberg earlier reported it sought a $50 billion valuation).

8.0

RESEARCH · 1 SOURCE · MIT Technology Review AI

Anthropic says Claude agents in new molecular-biology lab made a 'discovery'; scientists push back

Anthropic announced it launched a molecular-biology lab where 950 Claude agents assisted researchers and, after 21 hours, flagged a previously uncatalogued repeating pattern around a known enzyme that the company called a discovery. Several biologists and figures including Eli Lilly’s leadership criticized the characterization, noting the pattern is not a new sequence, that functional validation is the hard part, and that a Copenhagen researcher says his team had already found the pattern (Anthropic denies using his chats).

6.0